ARUK UCL Drug Discovery Institute Seminar Series

Non-Invasive Sensory Stimulation at Gamma Frequency as a Potential Therapeutic Intervention for Alzheimer’s Disease

Mihály Hajós, PharmD, PhD, Cognito Therapeutics, Cambridge, MA, and Yale University School of Medicine, New Haven, CT, USA

It is my pleasure to invite you to join us for this seminar by Mihaly Hajos, CSO, Cognito Therapeutics. Cognito Therapeutics is a Neurotechnology company founded by Profs Ed Boyden and Lihuei Tsai of MIT and the company is currently running a Phase 3 trial in AD patients. You can learn more about Cognito Therapeutics here. The original preclinical studies supporting this translation are presented in this Nature publication and this Cell publication.

Mihaly Hajos is the chief scientific officer at Cognito Therapeutics, and Professor Adjunct at Yale University School of Medicine.  Mihaly is a neurophysiologist, applying neurophysiological methods to study psychiatric and neurological diseases and developing treatment options for these illnesses, recently focusing on Alzheimer’s disease.

At Cognito Therapeutics, Mihaly’s main goal is translating experimental findings to clinics, which demonstrate that sensory-evoked gamma oscillatory activity modifies Alzheimer’s disease pathology and diminishes neurodegeneration. Mihaly is particularly interested in designing and developing translational biomarkers for understanding the interaction between abnormal activities of neuronal circuits and pathological mechanisms in Alzheimer’s disease. 

Mihaly had both academic and industrial positions, including positions as principal investigator at Pfizer and Biogen, and faculty member at Oxford University Clinical Medicine and Yale University School of Medicine.  Mihaly graduated from University of Szeged, Hungary, and received his PhD from University of Gothenburg, Sweden.  He published over 120 scientific papers, and he is recognized as a thought leader in translational medicine and CNS biomarkers.